# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Calidi Biotherapeutics shares are trading lower by 14.3% during Monday's session. The company announced a 1-for-10 reverse ...
Ladenburg Thalmann analyst Aydin Huseynov initiates coverage on Calidi Biotherapeutics (AMEX:CLDI) with a Buy rating and ann...